PAVmed added Exact Sciences founder and former chair Stanley Lapidus as a strategic adviser for its Lucid Diagnostics subsidiary.
Mr. Lapidus will help advance Lucid's EsoGuard and EsoCheck commercialization efforts.
Lucid is creating a series of noninvasive diagnostic tests to identify esophageal cancer and Barrett's esophagus.
Mr. Lapidus said: "Lucid Diagnostics' EsoGuard and EsoCheck technologies have the potential to be game changers in the diagnosis of conditions along the spectrum from Barrett's Esophagus to esophageal cancer, which is a growing scourge. ... I look forward to working with them as they accelerate commercialization, embark on important IVD clinical trials and explore capital market strategies."